These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37215703)

  • 1. Policy analysis in the field of rare diseases in China: a combined study of content analysis and Bibliometrics analysis.
    Li X; Wu L; Yu L; He Y; Wang M; Mu Y
    Front Med (Lausanne); 2023; 10():1180550. PubMed ID: 37215703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding Aging Policies in China: A Bibliometric Analysis of Policy Documents, 1978-2019.
    Nan Y; Feng T; Hu Y; Qi X
    Int J Environ Res Public Health; 2020 Aug; 17(16):. PubMed ID: 32824512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolution of mental health related policies in China: A bibliometric analysis, 1987-2020.
    Li H; Zhou Q; Zhu H; Shi P; Shen Q; Zhang Z; Chen Z; Pu C; Xu L; Hu Z; Ma A; Gong Z; Xu T; Wang P; Wang H; Hao C; Li C; Hao M
    Front Public Health; 2022; 10():964248. PubMed ID: 36504965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analyzing national telemedicine policies in China from the perspective of policy instrument (1997-2020).
    Zhang W; He D; Wang G; Zhu C; Evans R
    Int J Med Inform; 2022 Oct; 166():104854. PubMed ID: 35981479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Quantitative analysis of national hygienic city policies in China from the perspective of policy tools].
    Zheng WJ; Yao HY; Liu JJ; Yu SC; Li YQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Sep; 54(9):988-992. PubMed ID: 32907290
    [No Abstract]   [Full Text] [Related]  

  • 7. [Policy analysis of disease control and prevention system in China from the perspective of policy instruments from 2000 to 2020].
    Yuan SS; Wang F; Qiu WQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Oct; 55(10):1181-1185. PubMed ID: 34706501
    [No Abstract]   [Full Text] [Related]  

  • 8. Towards Holistic Governance of China's E-Waste Recycling: Evolution of Networked Policies.
    Yang X; Miao X; Wu J; Duan Z; Yang R; Tang Y
    Int J Environ Res Public Health; 2020 Oct; 17(20):. PubMed ID: 33053709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mining and quantitative evaluation of COVID-19 policy tools in China.
    Liu J; Li N; Cheng L
    PLoS One; 2023; 18(4):e0284143. PubMed ID: 37027438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How China controls the Covid-19 epidemic through public health expenditure and policy?
    Jin H; Li B; Jakovljevic M
    J Med Econ; 2022; 25(1):437-449. PubMed ID: 35289700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on China's national policies regarding rare diseases.
    Ying Z; Gong L; Li C
    Intractable Rare Dis Res; 2021 Aug; 10(3):148-153. PubMed ID: 34466336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The challenge of healthcare big data to China's commercial health insurance industry: evaluation and recommendations.
    Wu J; Qiao J; Nicholas S; Liu Y; Maitland E
    BMC Health Serv Res; 2022 Sep; 22(1):1189. PubMed ID: 36138390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a pilot rare disease registry: a focus group study of initial steps towards the establishment of a rare disease ecosystem in Slovenia.
    Stanimirovic D; Murko E; Battelino T; Groselj U
    Orphanet J Rare Dis; 2019 Jul; 14(1):172. PubMed ID: 31288838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The policy-making trend analysis of municipal solid waste in China 1980-2015.
    Chu Z; Wu B; He Z; Zhuang J; Wang W
    Waste Manag Res; 2019 Jun; 37(6):601-610. PubMed ID: 30931836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of China's fight against COVID-19 from the perspective of policy tools-policy capacity.
    Zhu S; Feng S; Ning X; Zhou Y
    Front Public Health; 2022; 10():951941. PubMed ID: 36203691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the Status and Tendency of R&D Input in the Field of Rare Diseases Funded by the National Natural Science Foundation of China.
    Chang H; Chu W; Li X; Ma J; Li D; Yuan N
    Front Public Health; 2021; 9():729162. PubMed ID: 34712637
    [No Abstract]   [Full Text] [Related]  

  • 17. Selection of Policy Instruments on Integrated Care in China: Based on Documents Content Analysis.
    Yue X; Mu K; Liu L
    Int J Environ Res Public Health; 2020 Mar; 17(7):. PubMed ID: 32235602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical Insurance Information Systems in China: Mixed Methods Study.
    Li Y; Lu C; Liu Y
    JMIR Med Inform; 2020 Sep; 8(9):e18780. PubMed ID: 32673209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding "Internet Plus Healthcare" in China: Policy Text Analysis.
    Yang F; Shu H; Zhang X
    J Med Internet Res; 2021 Jul; 23(7):e23779. PubMed ID: 34309581
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.